[{"id":"1c9f6138-8d9a-47fc-a239-63c21b0bb4fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04815356","created_at":"2021-03-25T12:52:31.393Z","updated_at":"2024-07-02T16:34:38.088Z","phase":"Phase 1","brief_title":"Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant","source_id_and_acronym":"NCT04815356","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • JCAR018 • anti-CD22 CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 05/23/2022","start_date":" 05/23/2022","primary_txt":" Primary completion: 12/01/2036","primary_completion_date":" 12/01/2036","study_txt":" Completion: 12/01/2036","study_completion_date":" 12/01/2036","last_update_posted":"2024-06-05"},{"id":"dab15a96-876b-4fdc-b04d-c6d8c5e516df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02315612","created_at":"2021-01-18T10:58:15.939Z","updated_at":"2024-07-02T16:34:58.824Z","phase":"Phase 1","brief_title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","source_id_and_acronym":"NCT02315612","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JCAR018 • anti-CD22 CAR T"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 12/12/2014","start_date":" 12/12/2014","primary_txt":" Primary completion: 04/03/2019","primary_completion_date":" 04/03/2019","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-06-05"}]